How Drug Price Controls End Up Hurting Patients

I AM BIO

English - September 28, 2021 09:00 - 32 minutes - 29.7 MB - ★★★★★ - 67 ratings
Life Sciences Science Health & Fitness Medicine coronavirus covid virus biopharmaceuticals biotech patients biotechnology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The Elephant in the Room: What About HIV?

Next Episode: Escaping the Food Allergy Prison

They are not the household names, but the medications they are researching and developing could be the lifeline patients are waiting for. Today we explore how drug price controls—now making their way through Congress—could have unintended consequences for the small biotechs that are the engine of the drug development ecosystem. And even worse, for the patients who need them most.

Guests:

Ahmed Mousa, Pieris Pharmaceuticals

Daphne Zohar, PureTech Health

Peter Kolchinsky, RA Capital

Michele Oshman, BIO

Clare Thorpe, Library Services (AU)